• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

    25.20 UNCHANGED
    Streaming Delayed Price Updated: 3:23 PM EDT, May 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 25.20
    Bid (Size) 24.20 (1)
    Ask (Size) 26.05 (1)
    Prev. Close 25.20
    Today's Range 25.20 - 25.20
    52wk Range 23.32 - 25.87
    Shares Outstanding N/A
    Dividend Yield 8.30%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    XOMA Royalty Completes Sale of Kinnate Pipeline Assets
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
    From XOMA Royalty Corporation
    Via GlobeNewswire

    Performance

    YTD
    -1.6%
    -1.6%
    1 Month
    -1.1%
    -1.1%
    3 Month
    -0.6%
    -0.6%
    6 Month
    -1.6%
    -1.6%
    1 Year
    +0.4%
    +0.4%

    More News

    Read More
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty to Present at Investor Conferences in March
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Royalty Corporation
    Via GlobeNewswire
    XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
    From XOMA Corporation
    Via GlobeNewswire
    Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty to Present at Upcoming Investor Conferences in September
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Corporation Announces Closing of Tender Offer
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Declares Quarterly Preferred Stock Dividends
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
    From XOMA Corporation
    Via GlobeNewswire
    XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
    From XOMA Corporation
    Via GlobeNewswire
    XOMA to Present at Upcoming Investor Conferences in March
    From XOMA Corporation
    Via GlobeNewswire

    Frequently Asked Questions

    Is XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative publicly traded?
    Yes, XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is publicly traded.
    What exchange does XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trade on?
    XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trades on the Nasdaq Stock Market
    What is the ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
    The ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is XOMAO on the Nasdaq Stock Market
    What is the current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
    The current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is 25.20
    When was XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative last traded?
    The last trade of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative was at 05/01/25 03:23 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.